Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07685249 · ClinicalTrials.gov registry record · NA
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
A NA study, sponsored by Duke University.
- Not yet
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07685249: Clinical Trial NA study, sponsored by Duke University.
NCT07685249 is a NA study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07685249, a NA study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment. All participants receive pelvic floor physical therapy and education about penile rehabilitation, including use of a vacuum erection device. Participants are randomly assigned to one of two groups. One group receives pelvic floor physical therapy plus telehealth sex therapy, with about ten sessions over six months. The other group receives pelvic floor physical therapy alone. Participants complete questionnaires about urinary and sexual health at the start of the study and over the next two years. Short interviews are also done at 6 and 12 months. Medicines for erectile function are prescribed as part of usual clinical care and are not part of the study treatment.
Primary Outcome
Accrual rate will be used to assess feasibility of recruiting participants to the study target of 30 participants. This feasibility trial is designed to estimate key process parameters with precision rather than to test efficacy hypotheses
Interventions
- BEHAVIORAL Pelvic Floor Physical Therapy
- BEHAVIORAL Sex Therapy
- DEVICE Vacuum Erection Device (VED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-07 |
| Phase | NA |
What is known before NCT07685249 opens enrollment
NCT07685249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Pelvic Floor Physical Therapy is the first listed.
NCT07685249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07685249 about?
NCT07685249 is a clinical study titled "Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment". This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment. All participants receive pelvic floor physical therapy and educ...
What is the current status of trial NCT07685249?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-07. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07685249?
The interventions under investigation include: Pelvic Floor Physical Therapy (BEHAVIORAL), Sex Therapy (BEHAVIORAL), Vacuum Erection Device (VED) (DEVICE).
Who is sponsoring clinical trial NCT07685249?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07685249's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia